Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment

Sclerostin, a protein produced by osteocytes, inhibits bone formation. Administration of sclerostin antibody results in increased bone formation in multiple animal models. Romosozumab, a humanized sclerostin antibody, has a dual effect on bone, transiently increasing serum biochemical markers of bon...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavassieux, Pascale, Chapurlat, Roland, Portero‐Muzy, Nathalie, Roux, Jean‐Paul, Garcia, Pedro, Brown, Jacques P, Libanati, Cesar, Boyce, Rogely W, Wang, Andrea, Grauer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027577/
https://www.ncbi.nlm.nih.gov/pubmed/31233639
http://dx.doi.org/10.1002/jbmr.3735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027577/
https://www.ncbi.nlm.nih.gov/pubmed/31233639
http://dx.doi.org/10.1002/jbmr.3735

Ejemplares similares